Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Pharmaceuticals (Basel) ; 17(4)2024 Apr 10.
Artículo en Inglés | MEDLINE | ID: mdl-38675445

RESUMEN

Lidocaine is the most commonly used local anesthetic worldwide, known for its rapid onset and moderate duration of anesthesia. However, it is short-lived and does not effectively promote effective topical anesthesia in the oral cavity when used alone. Our aim was to investigate whether an approximate 50% encapsulation of lidocaine in poly(ε-caprolactone) nanocapsules (LDC-Nano) would be able to increase its permeation and analgesic efficacy and reduce cytotoxicity. In this study, we characterized LDC-Nano and conducted MTT tests with HaCaT cells to assess their in vitro cytotoxicity. Additionally, in vitro permeation assays across the pig esophageal epithelium and the anesthetic efficacy of the hind paw incision model in rats were performed. Plain lidocaine (LDC) was compared with LDC-Nano and lidocaine hydrochloride plus epinephrine (LDC-Epi). The physicochemical characteristics of LDC-Nano were satisfactory (pH: 8.1 ± 0.21; polydispersity index: 0.08 ± 0.01; mean diameter (nm): 557.8 ± 22.7; and encapsulation efficiency (%): 51.8 ± 1.87) and remained stable for up to 4 months. LDC-Nano presented similar in vitro cytotoxicity to LDC but was higher than LDC-Epi (LD50: LDC = 0.48%; LDC-Nano = 0.47%; and LDC-Epi = 0.58%; p < 0.0001). Encapsulation increased the permeability coefficient about 6.6 times and about 7.5 the steady-state flux of lidocaine across the mucosal epithelium. Both encapsulation and epinephrine improved anesthesia duration, with epinephrine demonstrating superior efficacy (100% of animals were anesthetized up to 100, 30, and 20 min when LDC-Epi, LDC-nano, and LDC were used, respectively). Although LDC-Epi demonstrated superior in vivo anesthetic efficacy, the in vitro permeation and cytotoxicity of LDC-Nano indicate promising avenues for future research, particularly in exploring its potential application as a topical anesthetic in the oral cavity.

2.
PLoS One ; 16(2): e0246760, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33571275

RESUMEN

To determine whether the permeation capacity and analgesic efficacy of articaine (ATC) could be increased and cytotoxicity decreased by encapsulation in poly(ɛ-caprolactone) nanocapsules (ATCnano), aiming at local or topical anesthesia in dentistry. Cellular viability was evaluated (using the MTT test and fluorescence microscopy) after 1 h and 24 h exposure of HaCaT cells to ATC, ATCnano, ATC with epinephrine (ATCepi), and ATC in nanocapsules with epinephrine (ATCnanoepi). The profiles of permeation of 2% ATC and 2% ATCnano across swine esophageal epithelium were determined using Franz-type vertical diffusion cells. Analgesic efficacy was evaluated with a von Frey anesthesiometer in a postoperative pain model in rats, comparing the 2% ATC, 2% ATCnano, 2% ATCepi, and 2% ATCnanoepi formulations to 4% ATCepi (a commercially available formulation). We show that use of the nanocapsules decreased the toxicity of articaine (P<0.0001) and increased its flux (P = 0.0007). The 2% ATCepi and 4% ATCepi formulations provided higher analgesia success and duration (P<0.05), compared to 2% ATC, 2% ATCnano, and 2% ATCnanoepi. Articaine-loaded poly(ɛ-caprolactone) nanocapsules constitute a promising formulation for intraoral topical anesthesia (prior to local anesthetic injection), although it is not effective when injected in inflamed tissues for pain control, such as irreversible pulpitis.


Asunto(s)
Anestesia Dental/métodos , Anestesia Local/métodos , Carticaína/administración & dosificación , Nanocápsulas/administración & dosificación , Animales , Línea Celular , Supervivencia Celular/efectos de los fármacos , Humanos , Queratinocitos/efectos de los fármacos , Ratas , Ratas Wistar
3.
J Pharm Pharmacol ; 68(6): 791-802, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-27061827

RESUMEN

OBJECTIVES: The aim of this study was to observe the effect multilamellar liposomes (MLV) and 2-hydroxypropyl-ß-cyclodextrin (HP-ß-CD) in the in-vitro effects of lidocaine in cell viability, pro-inflammatory cytokines and prostaglandin E2 release of both human keratinocytes (HaCaT) and gingival fibroblasts (HGF) cells. METHODS: HaCaT and HGF cells were exposed to lidocaine 100-1 µm in plain, MLV and HP-ß-CD formulations for 6 h or 24 h. The formulation effects in cell viability were measured by XTT assay and by fluorescent labelling. Cytokines (IL-8, IL-6 and TNF-α) and PGE2 release were quantified by ELISA. KEY FINDINGS: MLV and HP-ß-CD formulations did not affect the HaCaT viability, which was significantly decreased by plain lidocaine after 24 h of exposure. Both drug carriers increased all cytokines released by HGF after 24-h exposure, and none of the carriers was able to reduce the PGE2 release induced by lidocaine. CONCLUSION: The effect of drug carrier in the lidocaine effects was dependent on the cell type, concentration and time of exposure. MLV and HP-ß-CD showed benefits in improving cell viability; however, both of them showed a tendency to increase cytokine release when compared to the plain solution.


Asunto(s)
Anestésicos Locales/farmacología , Fibroblastos/efectos de los fármacos , Encía/efectos de los fármacos , Mediadores de Inflamación/metabolismo , Queratinocitos/efectos de los fármacos , Lidocaína/farmacología , Lípidos/química , beta-Ciclodextrinas/química , 2-Hidroxipropil-beta-Ciclodextrina , Anestésicos Locales/química , Anestésicos Locales/toxicidad , Línea Celular , Supervivencia Celular/efectos de los fármacos , Citocinas/metabolismo , Dinoprostona/metabolismo , Relación Dosis-Respuesta a Droga , Composición de Medicamentos , Fibroblastos/metabolismo , Fibroblastos/patología , Encía/metabolismo , Encía/patología , Humanos , Queratinocitos/metabolismo , Queratinocitos/patología , Lidocaína/química , Lidocaína/toxicidad , Lípidos/toxicidad , Liposomas , Factores de Tiempo , beta-Ciclodextrinas/toxicidad
4.
Adv Pharm Bull ; 6(4): 573-579, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-28101464

RESUMEN

Purpose: The aim of this study was to evaluate the antibothropic and anti-inflammatory properties of J. elliptica.Methods: Phytochemical screening and thin-layer chromatography (TLC) assays were performed on J. elliptica hydroalcoholic extract (TE) in order to observe its main constituents. The antibothropic activity of TE was evaluated by the in vitro neuromuscular blockade caused by Bothrops jararacussu venom (Bjssu), in a mouse phrenic nerve-diaphragm model (PND). A quantitative histological study was carried out to observe a possible protection of TE against the venom myotoxicity. The anti-inflammatory activity was also evaluated in two models, Bjssu-induced paw edema, and carrageenan-induced neutrophils migration in the peritoneal cavity. Results: TLC analysis revealed several compounds in TE, such as saponins, alkaloids, and phenolic constituents. TE was able to neutralize the blockade and the myotoxicity induced by venom, when it was pre-incubated for 30 min with venom. In addition, it showed anti-inflammatory activity, inducing less neutrophils migration and reducing paw edema. Conclusion:J. elliptica showed both antibothropic and anti-inflammatory properties.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA